Successful Treatment of IL‐23 Inhibitor–Refractory Nail Psoriasis With Deucravacitinib: A Case Report

Nail psoriasis is a prevalent chronic inflammatory disorder that affects the nail unit and is often accompanied by psoriatic skin lesions. It is also more likely to progress to psoriatic arthritis. Here, we report the case of a 57‐year‐old woman who presented with a 3‐year history of nail dystrophy, scaling erythema, and psoriatic plaques on her body. The patient was treated with guselkumab for 1 year with a poor effect on her nail disorders and developed arthritic pain during the guselkumab treatment. Musculoskeletal ultrasound confirmed enthesitis. Subsequently, she was prescribed deucravacitinib at a dose of 6 mg once daily. Following this treatment, there was a marked improvement in both her nail lesions and arthritic swelling. Deucravacitinib may thus offer a valuable treatment option for refractory nail psoriasis.